Abstract
Background: Although peripheral blood adipokines and insulin levels have been considered to be biomarkers of Alzheimer’s disease (AD), previous researches about levels of adipokines and insulin in blood are no conclusive. We designed this meta-analysis to validate whether peripheral adipokines and insulin can be used as a candidate biomarker in AD diagnosis. Methods: We carried out a replication study in serum by ourselves and further conducted a meta-analysis to estimate the different levels of peripheral blood adipokines and insulin between AD patients and controls. In the section of meta-analysis, the pooled weighted mean difference (WMD) and 95% confidence interval (CI) was used to compare the levels of adipokines and insulin in different groups. Results: According to our replication study, there is statistically significant lower in the levels of leptin, but conspicuous higher in the levels of adiponectin and insulin in the blood of AD patients than controls. We finally identified four studies for leptin, four studies for adiponectin and eleven studies for insulin. From the random-effect model, the pooled WMD of the levels of leptin, adiponectin and insulin of AD subjects compared with the controls was -3.90 ng/ml (95% CI: [-5.68, -2.13]), 9.42 µg/mL (95% CI: [4.21, 14.62]), and 2.86 µIU/ml (95% CI: [1.21, 4.50]), respectively. Conclusion: Our replication study and meta-analysis support lower levels of leptin and higher levels of adiponectin and insulin in AD patients with respect to controls, and indicate their potential values as important risk factors for AD. Further researches that using standardized assay for leptin, adiponectin, and insulin measurement are still needed to reveal the potential change of peripheral blood leptin, adiponectin, and insulin levels in AD participants.
Keywords: Alzheimer’s disease, adipokines, leptin, adiponectin, insulin, plasma, serum.
Current Alzheimer Research
Title:Peripheral Blood Adipokines and Insulin Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analysis
Volume: 13 Issue: 3
Author(s): Jing Ma, Wei Zhang, Hui-Fu Wang, Zi-Xuan Wang, Teng Jiang, Meng-Shan Tan, Jin-Tai Yu and Lan Tan
Affiliation:
Keywords: Alzheimer’s disease, adipokines, leptin, adiponectin, insulin, plasma, serum.
Abstract: Background: Although peripheral blood adipokines and insulin levels have been considered to be biomarkers of Alzheimer’s disease (AD), previous researches about levels of adipokines and insulin in blood are no conclusive. We designed this meta-analysis to validate whether peripheral adipokines and insulin can be used as a candidate biomarker in AD diagnosis. Methods: We carried out a replication study in serum by ourselves and further conducted a meta-analysis to estimate the different levels of peripheral blood adipokines and insulin between AD patients and controls. In the section of meta-analysis, the pooled weighted mean difference (WMD) and 95% confidence interval (CI) was used to compare the levels of adipokines and insulin in different groups. Results: According to our replication study, there is statistically significant lower in the levels of leptin, but conspicuous higher in the levels of adiponectin and insulin in the blood of AD patients than controls. We finally identified four studies for leptin, four studies for adiponectin and eleven studies for insulin. From the random-effect model, the pooled WMD of the levels of leptin, adiponectin and insulin of AD subjects compared with the controls was -3.90 ng/ml (95% CI: [-5.68, -2.13]), 9.42 µg/mL (95% CI: [4.21, 14.62]), and 2.86 µIU/ml (95% CI: [1.21, 4.50]), respectively. Conclusion: Our replication study and meta-analysis support lower levels of leptin and higher levels of adiponectin and insulin in AD patients with respect to controls, and indicate their potential values as important risk factors for AD. Further researches that using standardized assay for leptin, adiponectin, and insulin measurement are still needed to reveal the potential change of peripheral blood leptin, adiponectin, and insulin levels in AD participants.
Export Options
About this article
Cite this article as:
Ma Jing, Zhang Wei, Wang Hui-Fu, Wang Zi-Xuan, Jiang Teng, Tan Meng-Shan, Yu Jin-Tai and Tan Lan, Peripheral Blood Adipokines and Insulin Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analysis, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/156720501303160217111434
DOI https://dx.doi.org/10.2174/156720501303160217111434 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Interaction Study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 Kinase and JNK Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis
Current Pharmaceutical Design Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics Ghrelin and Metabolic Disorders
Current Protein & Peptide Science Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases
Recent Patents on Biomarkers Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design Nanotechnology in Insulin Delivery for Management of Diabetes
Pharmaceutical Nanotechnology Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry Novel Monocyte Biomarkers of Atherogenic Conditions
Current Pharmaceutical Design A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Novel Natural Agents from Lamiaceae Family: An Evaluation on Toxicity and Enzyme Inhibitory Potential Linked to Diabetes Mellitus
Current Bioactive Compounds Combination of MafA, PDX-1 and NeuroD is a Useful Tool to Efficiently Induce Insulin-Producing Surrogate β -Cells
Current Medicinal Chemistry SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature
Current Clinical Pharmacology Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry The Functional Logic of Cytosolic 5’-Nucleotidases.
Current Medicinal Chemistry Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design